CVKD
Cadrenal Therapeutics Inc
NASDAQ · Pharmaceuticals
$5.70
+0.36 (+6.74%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 2.07M | 2.13M | 1.91M |
| Net Income | 662.5K | 666.1K | 461.6K |
| EPS | — | — | — |
| Profit Margin | 32.0% | 31.3% | 24.1% |
| Rev Growth | +2.5% | +18.2% | +2.4% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 1.76M | 1.83M | 1.72M |
| Total Equity | 9.55M | 9.25M | 9.23M |
| D/E Ratio | 0.18 | 0.20 | 0.19 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 955.8K | 1.01M | 1.06M |
| Free Cash Flow | 570.9K | 515.8K | 427.8K |